Search: WFRF:(Van't Veer Laura J.) >
Use of Molecular To...
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades
-
- Esserman, Laura J. (author)
- University of Calif San Francisco, CA 94115 USA
-
- Yau, Christina (author)
- University of Calif San Francisco, CA 94115 USA; Buck Institute Research Aging, CA USA
-
- Thompson, Carlie K. (author)
- University of Calif San Francisco, CA 94115 USA
-
show more...
-
- vant Veer, Laura J. (author)
- University of Calif San Francisco, CA 94115 USA
-
- Borowsky, Alexander D. (author)
- University of Calif Davis, CA 95616 USA
-
- Hoadley, Katherine A. (author)
- University of N Carolina, NC USA
-
- Tobin, Nicholas P. (author)
- Karolinska Institutet
-
- Nordenskjöld, Bo (author)
- Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US
-
- Fornander, Tommy (author)
- Karolinska Institutet
-
- Stål, Olle (author)
- Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US
-
- Benz, Christopher C. (author)
- University of Calif San Francisco, CA 94115 USA; Buck Institute Research Aging, CA USA
-
- Lindstrom, Linda S. (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- AMER MEDICAL ASSOC, 2017
- 2017
- English.
-
In: JAMA Oncology. - : AMER MEDICAL ASSOC. - 2374-2437 .- 2374-2445. ; 3:11, s. 1503-1510
- Related links:
-
https://jamanetwork....
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- IMPORTANCE The frequency of cancers with indolent behavior has increased with screening. Better tools to identify indolent tumors are needed to avoid overtreatment. OBJECTIVE To determine if a multigene classifier is associated with indolent behavior of invasive breast cancers in women followed for 2 decades. DESIGN, SETTING, AND PARTICIPANTS This is a secondary analysis of a randomized clinical trial of tamoxifen vs no systemic therapy, with more than 20-year follow-up. An indolent threshold (ultralow risk) of the US Food and Drug Administration-cleared MammaPrint 70-gene expression score was established above which no breast cancer deaths occurred after 15 years in the absence of systemic therapy. Immunohistochemical markers (n = 727 women) and Agilent microarrays, for MammaPrint risk scoring (n = 652 women), were performed from formalin-fixed paraffin-embedded primary tumor blocks. Participants were postmenopausal women with clinically detected node-negative breast cancers treated with mastectomy or lumpectomy and radiation enrolled in the Stockholm tamoxifen (STO-3) trial, 1976 to 1990. EXPOSURES After 2 years of tamoxifen vs no systemic therapy, regardless of hormone receptor status, patients without relapse who reconsented were further randomized to 3 additional years or none. MAIN OUTCOMES AND MEASURES Breast cancer-specific survival assessed by Kaplan-Meier analyses and multivariate Cox proportional hazard modeling, adjusted for treatment, patient age, year of diagnosis, tumor size, grade, hormone receptors, and ERBB2/HER2 and Ki67 status. RESULTS In this secondary analysis of node-negative postmenopausal women, conducted in the era before mammography screening, among the 652 women with MammaPrint scoring available (median age, 62.8 years of age), 377 (58%) and 275 (42%) were MammaPrint low and high risk, respectively, while 98 (15%) were ultralow risk. At 20 years, women with 70-gene high and low tumors but not ultralow tumors had a significantly higher risk of disease-specific death compared with ultralow-risk patients by Cox analysis (hazard ratios, 4.73 [95% CI, 1.38-16.22] and 4.54 [95% CI, 1.40-14.80], respectively). There were no deaths in the ultralow-risk tamoxifen-treated arm at 15 years, and these patients had a 20-year disease-specific survival rate of 97%, whereas for untreated patients the survival rate was 94%. Recursive partitioning identified ultralow risk as the most significant predictor of good outcome. In tumors "not ultralow risk," tumor size greater than 2 cm was the most predictive of outcome. CONCLUSIONS AND RELEVANCE The ultralow-risk threshold of the 70-gene MammaPrint assay can identify patients whose long-term systemic risk of death from breast cancer after surgery alone is exceedingly low.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Esserman, Laura ...
-
Yau, Christina
-
Thompson, Carlie ...
-
vant Veer, Laura ...
-
Borowsky, Alexan ...
-
Hoadley, Katheri ...
-
show more...
-
Tobin, Nicholas ...
-
Nordenskjöld, Bo
-
Fornander, Tommy
-
Stål, Olle
-
Benz, Christophe ...
-
Lindstrom, Linda ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
JAMA Oncology
- By the university
-
Linköping University
-
Karolinska Institutet